My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 500126 | NSE: PGHL | Pharmaceuticals & Drugs | Small Cap
1. Is Procter & Gamble Health Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Procter & Gamble Health Ltd is a good quality company.
2. Is Procter & Gamble Health Ltd undervalued or overvalued?
The key valuation ratios of Procter & Gamble Health Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
3. Is Procter & Gamble Health Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Procter & Gamble Health Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | TTM | |||
| ROCE % ⓘ | 11% | 7.9% | 9.2% | 12.3% | 6.8% | 8.5% | 20.8% | 22.2% | 29.3% | 33.5% | - | ||
| Value Creation Index ⓘ | -0.2 | -0.4 | -0.3 | -0.1 | -0.5 | -0.4 | 0.5 | 0.6 | 1.2 | 1.5 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 798 | 867 | 940 | 993 | 698 | 849 | 904 | 1,009 | 1,114 | 1,230 | 1,237 | ||
| YoY Gr. Rt. % | - | 8.7% | 8.3% | 5.7% | -29.7% | 21.6% | 6.5% | 11.6% | 10.5% | 10.3% | - | ||
| Adj EPS ⓘ | 33.4 | 25.5 | 31.7 | 46.6 | 28.8 | 58.1 | 102.2 | 107.1 | 116.5 | 137.8 | 139.4 | ||
| YoY Gr. Rt. % | - | -23.4% | 24.2% | 47.1% | -38.3% | 102.1% | 75.9% | 4.8% | 8.8% | 18.3% | - | ||
| BVPS (₹) ⓘ | 315.1 | 333.9 | 356.4 | 399.9 | 441.7 | 927.8 | 363.2 | 421.6 | 367 | 447.6 | 487.1 | ||
| Adj Net Profit ⓘ | 55.4 | 42.4 | 52.6 | 77.4 | 47.8 | 96.5 | 170 | 178 | 193 | 229 | 231 | ||
| Cash Flow from Ops. ⓘ | 0.5 | 5 | 83.5 | 107 | 53.7 | -130 | 157 | 247 | 170 | 236 | - | ||
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 4.9% | 12% | 10.8% | 10.3% | ||||||||
| Adj EPS ⓘ | 17.1% | 36.8% | 10.5% | 18.3% | ||||||||
| BVPSⓘ | 4% | 0.3% | 7.2% | 22% | ||||||||
| Share Price | 23.4% | 12.1% | -9.3% | 26.4% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | TTM | ||
| Return on Equity % ⓘ | 11 | 7.9 | 9.2 | 12.3 | 6.8 | 8.5 | 20.8 | 22.1 | 29.3 | 33.5 | 29.8 | |
| Op. Profit Mgn % ⓘ | 9.7 | 6.8 | 9 | 11.7 | 10.1 | 17 | 23.4 | 24.5 | 24.1 | 26.4 | 26.2 | |
| Net Profit Mgn % ⓘ | 6.9 | 4.9 | 5.6 | 7.8 | 6.8 | 11.4 | 18.8 | 17.6 | 17.4 | 18.6 | 18.7 | |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |
| Working Cap Days ⓘ | 263 | 274 | 381 | 367 | 503 | 486 | 346 | 491 | 438 | 423 | 0 | |
| Cash Conv. Cycle ⓘ | 74 | 85 | 82 | 66 | 88 | 49 | 12 | -3 | -22 | -31 | 0 | |
Return on Equity has increased versus last 3 years average to 29.80%
Sales growth is growing at healthy rate in last 3 years 10.80%
Net Profit is growing at healthy rate in last 3 years 10.47%
Sales growth is not so good in last 4 quarters at 8.91%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 139.4 | - |
| TTM Sales (₹ Cr.) | 1,237 | - |
| BVPS (₹.) ⓘ | 487.1 | - |
| Reserves (₹ Cr.) ⓘ | 792 | - |
| P/BV ⓘ | 10.62 | - |
| PE ⓘ | 37.12 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 3886.10 / 5496.50 |
| All Time Low / High (₹) | 114.00 / 7499.95 |
| Market Cap (₹ Cr.) | 8,588 |
| Equity (₹ Cr.) | 16.6 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43.7 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Procter & Gamble Health Limited (formerly Merck Limited) was set up in India as one of Merck’s Asian subsidiaries in 1967. It was also the first Merck Group Company to go public in the year 1981. Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country.
On December 1st, 2018, P&G successfully completed the acquisition of Merck’s Consumer Health business further to approval of all relevant regulatory authorities and the fulfilment of other customary closing conditions. Procter & Gamble Overseas India B.V. now holds 51.81% of the share capital in Merck Limited, while the remaining 48.19% is traded on the Bombay Stock Exchange Ltd. and National Stock Exchange of India Ltd.
Currently, Procter & Gamble Health Limited (formerly Merck Limited) is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life. With a strong portfolio of brands backed by science and trusted by doctors, pharmacists and consumers, Procter & Gamble Health Limited combines the best of P&G and Legacy Merck’s Consumer Health capabilities and cultures. Together we are working towards leveraging our combined expertise to develop categories and brands that meet today’s needs and tomorrow’s opportunities.
Situated at Usgaon, Goa, the company’s Manufacturing Site has grown from a small Vitamin E producing unit to a big composite plant manufacturing pharma and chemical products.
Business area of the company
Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country. The company is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life.
Brands of the company
Awards and achievements
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
